Summary.-Equimolar concentrations of cysteamine and reduced glutathione protected against the cytotoxicity of 5mm misonidazole (MISO), whereas 5mM ascorbate enhanced its toxicity to hypoxic CHO and HeLa cells in vitro. Protection (reappearance of a shoulder region) could also be seen when cysteamine was added at later incubation times. These changes in toxicity were accompanied by changes in drug metabolism, as evidenced by radiochromatograms of cell extracts obtained after treatment with 14C-labelled MISO. In contrast, radiochromatograms obtained from cells treated with toxic levels of MISO (75mm) under aerobic conditions indicated no drug metabolism. Both toxicity and drug metabolism could be immediately halted by introducing 02 during hypoxic exposures to MISO. These observations are discussed in terms of a possible model for the metabolism-mediated toxicity of MISO and the roles which sulphydryls and 02 may play.
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RAPIDLY GROWING tumour tissue with poor vascularization may contain regions of radioresistant but viable hypoxic cells. The possibility that hypoxic cells may be a limiting factor in achieving local tumour control in some radiotherapy regimes has led to the development of a class of compounds which can sensitize hypoxic tumour cells to ionizing radiation damage. Misonidazole (1-(2 -nitro-1 -imidazolyl)-3-methoxy-2-propanol, MISO) an electronaffinic nitroheterocyclic radiosensitizer, is currently undergoing clinical investigation (Dische, 1978; Urtasun et al., 1977; Wasserman et at., 1979) . Because of an additional preferential cytotoxicity toward hypoxic cells in the absence of radiation (Hall & Roizin-Towle, 1975; Moore et al., 1976 ) a chemotherapeutic use of this compound in the treatment of noncycling hypoxic tumour cells can also be envisaged. This toxicity is dependent upon temperature Stratford & Adams, 1977) , 02 concentration (Stratford, 1978; Taylor & Rauth, 1978) and cell line Taylor & Rauth, 1978) and appears to involve an oxygen-sensitive reductive metabolism of the drug (Varghese et al., 1976; Wong et al., 1978) to what may be the ultimate cytotoxic agent(s). Still other factors influencing the cytotoxicity of some nitroheterocyclic radiosensitizers may be of clinical importance. Among these factors are tissue enzyme levels, which may enhance drug metabolism, and the presence of certain cellular reducing species. Ascorbate (ASC) has been shown to increase the cytotoxicity of MISO toward hypoxic Chinese hamster ovary (CHO) cells (Josephy et al., 1978) while cysteamine (MEA), a radical scavenger and radioprotector, has been shown to protect against its cytotoxic effects . This raises the question whether or not the ASC-enhanced toxicity of MISO (Josephy et al., 1978; Koch et al., 1979 ) is mediated by an increased formation of toxic drug metabolites. Evidence is presented in this paper that ASC does t To whom requests for reprints should be sent.
promote the reduction of MISO, leading to a greater accumulation of drug metabolites in the cell. Also the effects of MEA and reduced glutathione (GxSH) on the metabolism of MISO have been investigated. These results are discussed in terms of a possible model implicating sulphydryl (R-SH) depletion in the hypoxic cell toxicity of MISO.
MATERIALS AND METHODS
Colony-forming assays were carried out as described previously (Taylor & Rauth, 1978) to assess the toxicity of MISO under hypoxic conditions in the presence of the following reducing agents: cysteamine HCI, reduced glutathione (Sigma Chemical Co., St Louis, Mo) and ascorbate (Gibco Canada, Burlington, Ont.). MISO was a gift from C. E. Smithen (Roche Products, Welwyn Garden City, England). Appropriate concentrations of all drugs were freshly prepared in otmedium (Stanners et al., 1971) Koch & Kruuv (1972) .
Descending paper chromatography procedures as described previously by Taylor & Rauth (1978) In preliminary experiments each strip of the cell chromatograms was eluted in 2 ml distilled water before counting and the optical density of the eluate measured at 325 nm to determine whether the NO2 group of MISO was still intact. Fig. 1 shows the survival of hypoxic CHO cells exposed to 5mM MISO in the presence of equimolar concentrations of ASC, GSH and MEA. The results in the presence of ASC indicate an enhancement of the cytotoxic effects of MISO whereas the 2 sulphydryl compounds appear to reduce this toxicity, MEA being the more effective. These effects are seen mainly as modifications of the shoulder region of the survival curves (Fig. 1) . The survival of cells treated with both ASC and MEA in combination with MISO (data not shown) looked very similar to the curve for MISO +GSH in Fig. 1 , indicating a slight predominance of the protective effect of the SH-containing compound.
RESULTS
The results obtained when HeLa cells were exposed to 5mM MISO in the presence of equimolar concentrations of ASC or MEA are shown in Fig. 2 (Varghese & Whitmore, 1980) and appear to react with non-protein thiols (Varnes et al., 1980 derivative of MISO (Varghese et al., 1976 and personal communication). The top 2 panels also reflect the differences in the rate of drug metabolism noted earlier for these 2 cell lines (Taylor & Rauth, 1978) . Panels B and F of Fig. 3 indicate the presence of the same peaks when cells are incubated with MISO + ASC. The increased quantity of metabolites here suggests that the ASC-enhanced toxicity of MISO is accompanied by an increased rate of drug metabolism. Panels C and G of Fig. 3 show the distribution when incubations are carried out in the presence of 5mM MEA. In contradiction to the most obvious prediction of decreased metabolism with decreased toxicity, a large increase is noted again in the quantity of nitro-reduced metabolites (no absorption at 325 nm) as well as the appearance of at least one new metabolite in the RF = 0415-0-4 region and another at RF=06. The distribution obtained in the presence of the less effective protective agent, GSH (Fig. 3D) is also characterized by an increase in the total quantity of nitroreduced metabolites and the appearance of at least one new metabolite in the RF= 015-0-4 region, though the total activity in the RF =0O4-0 6 region is considerably less than what is seen in CHO cells treated with MISO alone (Fig. 3A) . The variations in the peak RF values between the 2 experiments, represented by the right and left side of Fig. 3 , are of the order typically seen (± 003 RF units) with this chromatography procedure.
In order to see toxicity toward aerobic cells within the same time scale as for hypoxic cells, it is necessary to go to much higher MISO concentrations. The survival Hours in N2 Bearing in mind: (i) the regeneration of the shoulder region in the split-dose experiment (Fig. 5) , (ii) the modification of the shoulder region of MISO survival curves in the presence of ASC, GSH and MEA (Fig. 1) , and (iii) the possibility that R-SH depletion may play a role in the shoulder region of these survival curves, a test of the effects of the addition of MEA at the 10-2 survival level on subsequent cell survival in the presence of MISO was performed. The results of this experiment are shown in Fig. 6 , where it appears that the late addition of 5mM MEA, whilst maintaining the cells in a hypoxic state, regenerates most of the increased shoulder region seen when MEA is present from the start (Fig. 1) . No appreciable change in the MISO survival curve was noted when 5mM ASC was added at the 10-2 survival level (Fig. 6) . Fig. 7 shows the distribution of metabolites in CHO cells subjected to the experimental procedures used to obtain the survival data in Figs 5 and 6 . The top left panel shows the distribution of radioactivity after a 4-h hypoxic exposure to 5mM MISO (the 4'h point in Figs 5 and 6 ). This distribution is qualitatively similar to that seen in Fig. 3A for a 5h hypoxic incubation, though there is less activity in the form of MISO n3gtabolites after this shorter incubation. The top right panel shows the distribution of metabolites seen 2 h after the cells are reoxygenated in the split-dose experiment, and is also representative of what is seen after 4 h. This result suggests that metabolism of the drug is completely halted during the aerobic exposure, and that there is no appreciable leakage of these metabolites from the cells. The increased activity seen in the bottom left panel of Fig. 7 is consistent with the resumption of MISO metabolism when the cells are rendered hypoxic again and incubated for a further 3 h. The bottom right panel shows the distribution 2 h after 5mM MEA has been added to a culture previously exposed to MISO for 4-h under hypoxic conditions. There is an increased accumulation of metabolites as well as the rapid appearance of new metabolite(s) in the RF = 0-15-0-4 region, similar to that previously noted in Figs 3C and F when MEA was present during the entire incubation.
DISCUSSION
Enhancement of the toxicity of MISO in the presence of ASC was seen by Josephy et al. (1978) and Koch et al. (1979) as well as in the present investigation (Figs 1  and 2 ). The effect of 5mM ASC on the survival of CHO cells ( Fig. 1 and Josephy et al. 1978) appears to be greater than for HeLa (Fig. 2) or V79 cells, and is characterized by a large reduction in the shoulder region of the resulting survival curves. This is in contrast to the results of Koch et al. (1979) in which the influence of ASC was seen primarily as an increase in the slope of the exponential portion of survival curves obtained with monolayer Chinese hamster V79 cultures. Although their exposure conditions differed from those used here, the observed differences may reflect cellline variations. The results with HeLa cells (Fig. 2) more closely parallel the slope-modifying effect seen with V79 cells, though the time scale is much reduced for the more sensitive HeLa cell line.
The protective effects noted here (Figs  1 and 2 ) for MEA and GSH are consistent with previous reports Hall et al., 1977) . Further comparisons to distinguish slope-or shoulder-modifying effects cannot be made, since the above communications covered a more limited survival range. Protection was also noted by Stratford & Gray (1978) when the R-SH compound D-penicillamine was used in conjunction with MISO. Their results indicated an increase in the shoulder region of the survival curve, analogous to what was seen here for MEA and GSH (Fig. 1) accompanied by a small reduction in slope. In contrast to the protective effects seen by the above authors, one group found an increase in toxicity with GSH (Josephy et al., 1978) . Subsequent studies by this group (Palcic et al., 1980) indicated pH as a factor determining whether protection or enhanced toxicity is seen.
When MEA was used in combination with ASC, the protective effect of the R-SH compound predominated. also noted a predominance of the protective effects of R-SH compounds when used in combination with ASC. For both CHO (data not shown, see text) and HeLa (Fig. 2) cells, the exposure time required to reach a given survival level with the combination of agents can be predicted by the simple addition of the MEA protection and ASC sensitization effects. This calculation indicates a relatively larger protective effect for the combination in HeLa than in CHO cells, which was seen. These results suggest that an interaction between ASC and sulphydryls may be occurring in the cell.
The shoulder reappearance seen in the split-dose experiment (Fig. 5) To provide some framework within which to discuss these observations, a possible model for the metabolism-mediated toxicity of MISO and the roles which sulphydryls and 02 may play is shown in Fig. 8 . Site A represents the electrondonating species in the cell or nitroreductase. The enhanced metabolism when cells are incubated with MISO in the presence of ASC or MEA could be a consequence of a direct effect on the electrondonating capacities or nitro-reductase activities of the cell. No direct interactions under anoxic conditions between ASC and MIS could be detected, in a purely chemical system (data not shown). However, ASC has been previously shown to increase liver microsomal drug metabolism (e.g. NADPH-cytochrome c reductase, NADPH-cytochrome P-450 reductase; Zannoni & Sato, 1975) . The chemical reduction of MISO with Fe2+ ions and MEA reported by Bahnemann et al. (1978) could be reproduced here (data not shown). Further work is being done with this to compare the chemically produced metabolites with those seen in cell-extract chromatograms (Figs 3C and G) . The differences in the sensitivities of HeLa and CHO cells (Figs 1 and 2 ) have been shown to be associated with differences in rates of drug metabolism (Taylor & Rauth, 1978) and also may reflect differences at Site A.
Site B is where the inhibitory effects of 02 on the toxicity and metabolism of MISO noted in the split-dose experiments (Figs 5 and 7) are likely to occur. The toxicity of MISO at very high concentrations under aerobic conditions (Fig. 4) where no drug breakdown occurs may be mediated by the formation of excessive levels of peroxides and radicals from the oxidation of the nitro-radical back to the parent compound (Mason, 1979) .
Site C represents a short-lived toxic intermediate which is formed under hypoxic conditions and leads to cell death via reaction with some critical target, presumably DNA (Knight et al., 1979; Fig. 8 . A toxicity mechanism involving an early depletion of sulphydryls may give rise to the shoulder-region differences seen in Fig. 1 . The decrease in toxicity seen with MEA and GSH may be due to a longer time being required for R-SH depletion, whereas the increase in toxicity observed with ASC may be associated with a faster rate of R-SH depletion. Support for such a mechanism comes from the observations of Varnes et al. (1980) that MISO catalyses the depletion of intracellular non-protein thiols (NPSH) in hypoxic Ebrlich ascites, V79 and CHO cells. They also found the rate of NPSH depletion to be increased by 10mM ASC. Consistent with this mechanism is the reappearance of a shoulder region when MEA is added at the 10-2 survival level (Fig. 6 ). This mechanism could account for the appearance of new peaks in the chromatograms when cells are incubated with MISO in combination with GSH or MEA (Fig. 3) and for the rapid appearance of a similar metabolite when MEA is added at the 10-2 survival level (Fig. 7) if stable thiol adducts were formed. Preliminary attempts to identify a thiol adduct in the chromatographic distributions for (MISO + MEA)-treated cells were inconclusive.
It is unlikely that the modifying effects of ASC, GSH and MEA on the toxicity of MISO can be accounted for entirely by either an R-SH-depletion mechanism or changes in the rate of drug reduction to more reactive intermediates since both of these modes of operation are consistent with the results presented here and elsewhere. Furthermore a dual mode of action may account for some of the variability in the in vitro data. For example, the differing effects on the shape of survival curves seen for cells treated with ASC + MISO (shoulder effect: Fig. 1 ; slope effect (this paper) and Fig. 3 in Koch et al. (1979) ), may be the result of differences in the predominant mode of action in these situations. If ASC were operating at Site A in Fig. 8 and an increased rate of formation of toxic drug metabolite(s) resulted, the rate of cell killing might be affected. This might be expressed as a change in slope of the resulting survival curve. In contrast, a R-SH-depletion mechanism could account for a reduction in the shoulder region of survival curves.
Variations in tissue and individual nitro-reductase activities, ASC levels and R-SH levels could influence the human pharmacology of MISO and similar nitrogorup-containing compounds currently being investigated as hypoxic cell radiosensitizers and cytotoxic agents. Further work is necessary to characterize what role these factors play in the in vivo situation. Ultimately, an understanding of such factors should aid in the implementation of radiosensitizers to achieve the best possible therapeutic effect.
